Abstract Number: 1138 • ACR Convergence 2025
Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
Background/Purpose: Pozdeutinurad (AR882, POZD) is a novel, selective URAT1 inhibitor currently in phase 3 clinical stage development for the treatment of gout and tophaceous gout.…Abstract Number: 1143 • ACR Convergence 2025
Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
Background/Purpose: Gout is the most common form of inflammatory arthropathy, with a prevalence ranging from 0.1% to approximately 10% worldwide. Despite a well-established association between…Abstract Number: 1144 • ACR Convergence 2025
A quantitative study of renal medulla echogenicity in 250 Vietnames gout patients shows correlation with poor renal function
Background/Purpose: We previously described the frequent occurrence of an hyperechogenic pattern of the renal medulla following crystal deposition in untreated Vietnamese patients with severe tophaceous…Abstract Number: 1145 • ACR Convergence 2025
Numerically Reduced but MSU Crystal-Activated NK Cells Promote Osteoclastogenesis in Gout
Background/Purpose: Gout is an inflammatory arthritis characterized by acute attacks, tophi formation, and bone destruction triggered by inflammatory responses to monosodium urate (MSU) crystals. Natural…Abstract Number: 1146 • ACR Convergence 2025
Association of Walking Volume and Intensity With Incident Gout: A Population-based Cohort Study
Background/Purpose: Previous studies have reported that walking is associated with a lower risk of several metabolic diseases; however, evidence of its association with gout, a…Abstract Number: 1259 • ACR Convergence 2025
Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
Background/Purpose: Many patients with uncontrolled gout (UG) experience symptoms despite being on urate-lowering therapy (ULT), often requiring support from informal caregivers. UG impacts patients and…Abstract Number: 1799 • ACR Convergence 2025
Validating the Gouty Arthritis Alleviating Effects of Cerevisterol through Integrated In Silico, In Vitro, and In Vivo Studies
Background/Purpose: Zhuling has traditionally been utilized in the treatment of gouty arthritis (GA). Although its therapeutic benefits are recognized, the molecular mechanisms underlying Zhuling's action…Abstract Number: 1891 • ACR Convergence 2025
Geographic Trends in the Burden of Gout in the United States from 1990 to 2021: A State-Level Analysis of Prevalence, Incidence, and Disability
Background/Purpose: Gout, a chronic inflammatory arthritis driven by hyperuricemia, has become an increasingly significant cause of disability in the United States. Despite therapeutic advances, its…Abstract Number: 1903 • ACR Convergence 2025
Seasonal and Racial/Ethnic Variation in Achieving Target Uric Acid Levels in Gout Patients on Urate Lowering Therapy in US Veterans in Central California
Background/Purpose: Gout is a chronic, inflammatory arthritis driven by monosodium urate (MSU) crystal deposition and elevated serum uric acid (SUA) levels, increasing the risk for…Abstract Number: 1907 • ACR Convergence 2025
Twenty-Year Trends in the U.S. Burden of Gout: A State-Level Analysis of Disability and Prevalence from 2001 to 2021
Background/Purpose: Gout is the most common inflammatory arthritis and an important driver of chronic disability. However, long-term trends in gout burden across U.S. states are…Abstract Number: 1923 • ACR Convergence 2025
A Real-World Survey On Physicians’ Perspectives Of Uncontrolled Gout And Gout Management Practices.
Background/Purpose: Managing uncontrolled gout (UG) can involve a multi-disciplinary approach involving physicians of different specialities, all of whom may have differing perspectives or approaches for…Abstract Number: 1990 • ACR Convergence 2025
Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
Background/Purpose: Rheumatology guidelines endorse a treat-to-target (TTT) approach targeting serum urate (SU) < 6 mg/dL among patients with gout who qualify for urate-lowering therapy (ULT).…Abstract Number: 1992 • ACR Convergence 2025
Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT
Background/Purpose: Methotrexate (MTX) coadministered with pegloticase attenuates anti-drug antibody formation, leading to higher response rates and markedly reduced infusion reaction risk compared with pegloticase +…Abstract Number: 1993 • ACR Convergence 2025
Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
Background/Purpose: Gout may increase the risk of cardiovascular events (CVEs) and bone fractures through urate deposition and chronic inflammation1,2. However, the additional effects of uncontrolled…Abstract Number: 1995 • ACR Convergence 2025
The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study
Background/Purpose: Gout is an inflammatory-metabolic condition that is associated with a heavy burden of cardiovascular-kidney-metabolic (CKM) comorbidities. Accordingly, multimorbidity and polypharmacy are important considerations which…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »